How much does it cost to buy one tube of Tremelimumab?

Tremelimumab is an immune checkpoint inhibitor mainly used for the treatment of advanced or recurrent malignant tumors. Its core mechanism is to inhibit the CTLA-4 signal and relieve the immune suppression state of T cells, thereby enhancing the body's own anti-tumor immunity. Clinical studies have shown that temsitumumab has potential efficacy in advanced hepatocellular carcinoma, non-small cell lung cancer and some solid tumors. It is especially suitable for patients who have poor tolerance to traditional chemotherapy or who have failed multiple lines of treatment.

Currently, temsitumumab has not been approved for marketing in mainland China, so it cannot be obtained through domestic hospitals or medical insurance channels, and it is not included in medical insurance reimbursement items. If patients need to use the drug, they usually need to obtain it from overseas hospitals or Hong Kong. The overseas market specification is 300mg/15ml, and the price per vial is about RMB 100,000. There are no generic or alternative drugs available. The price is relatively high, but it is regarded as an innovative immunotherapy in the international market. Its precise regulation of the mechanism of action of the immune system makes it uniquely valuable in the treatment of advanced tumors.

The clinical use of temsitumumab usually requires doctors to evaluate the patient's overall condition, immune function and previous treatment history. Its adverse reactions include immune-related side effects, such as rash, liver function abnormalities, enteritis, thyroid dysfunction, etc., so strict monitoring and follow-up in the hospital are required. Some patients have shown better efficacy in combined treatment with PD-1/PD-L1 inhibitors. This combination strategy utilizes the synergy of different immune checkpoints to improve the response rate and therapeutic effect of advanced tumors.

Overall, temsitumumab, as an immune drug, has potential value in the treatment of advanced tumors. Although it has not yet been marketed in China, it has been used overseas and in Hong Kong and Macao. The price is relatively high and there are no generic drugs. However, its immune checkpoint inhibition mechanism provides a new treatment direction for patients with multiple drug-resistant or relapsed tumors.

Reference: https://www.drugs.com/mtm/tremelimumab.html